Utama › Leukemia Limfositik Kronik › Missouri › Kansas City
Kajian klinikal Leukemia Limfositik Kronik di Kansas City, MO
10 kajian untuk Leukemia Limfositik Kronik sedang mencari peserta di lokasi dalam dan sekitar Kansas City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Mengambil pesertaFasa 3
- MidAmerica Cancer Care, LLC ( Site 5426), Kansas City
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Mengambil pesertaFasa 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- dan 1 lagi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Kansas City Veterans Affairs Medical Center, Kansas City
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Mengambil pesertaFasa 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- Kansas City Veterans Affairs Medical Center, Kansas City
- dan 2 lagi
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Mengambil pesertaFasa 1/2
- The University of Kansas Cancer Center, Westwood · 5 mi jauh
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mengambil pesertaFasa 3
- The University of Kansas Cancer Center, Westwood · 5 mi jauh
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Mengambil pesertaFasa 3
- MidAmerica Cancer Care, LLC ( Site 0043), Kansas City
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Mengambil pesertaFasa 3
- Saint Lukes Hospital of Kansas City /ID# 267270, Kansas City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Mengambil pesertaFasa 1/2
- University of Kansas, Westwood · 5 mi jauh
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Mengambil pesertaFasa 2
- Kansas City VA Medical Center, Kansas City, MO, Kansas City
Kajian Leukemia Limfositik Kronik di bandar lain
- Boston, MA31 kajian
- Columbus, OH28 kajian
- Durham, NC27 kajian
- Washington, DC22 kajian
- Seattle, WA20 kajian
- Rochester, MN18 kajian
- New York City, NY18 kajian
- Houston, TX17 kajian
- Baldwin Park, CA16 kajian
- Milwaukee, WI15 kajian
- Chicago, IL14 kajian
- Cincinnati, OH14 kajian
Kajian lain di Kansas City
- Kanser Payudara34 kajian
- Kanser Paru-paru Bukan Sel Kecil31 kajian
- Kegagalan Jantung25 kajian
- Kanser (semua jenis)21 kajian
- Kanser Paru-paru19 kajian
- Kanser Kolorektal16 kajian
- Kanser Metastatik15 kajian
- Leukemia Mieloid Akut15 kajian
- Kanser Prostat14 kajian
- Kanser Ovari11 kajian
- Obesiti11 kajian
- Diabetes Jenis 211 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.